Chemotherapy Induced Peripheral Neuropathy Market Global Report 2028
[Informe de investigación] Se prevé que el mercado de la neuropatía periférica inducida por quimioterapia alcance los 1.174,26 millones de dólares en 2028 desde los 813,48 millones de dólares de 2021; Se espera que registre una CAGR del 5,4% de 2021 a 2028.neuropathy market is projected to reach US$ 1,174.26 million by 2028 from US$ 813.48 million in 2021; it is expected to register a CAGR of 5.4% from 2021 to 2028.
La neuropatía periférica inducida por la quimioterapia es uno de los efectos secundarios más frecuentes causados por los agentes antineoplásicos. Clínicamente, es una neuropatía principalmente sensorial que puede ir acompañada de cambios motores y autónomos de intensidad y duración variables. Debido a su alta prevalencia entre los pacientes con cáncer, la neuropatía periférica inducida por la quimioterapia constituye un problema importante tanto para los pacientes como para los sobrevivientes de cáncer, así como para sus proveedores de atención médica, especialmente porque, por el momento, no existe un método único eficaz para prevenirla; además, las posibilidades de tratar este síndrome son limitadas.neuropathy is one of the most frequent side effects caused by antineoplastic agents. Clinically, it is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, chemotherapy-induced peripheral neuropathy constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing it; moreover, the possibilities of treating this syndrome are limited.
Personalice la investigación para adaptarla a sus necesidades
Podemos optimizar y adaptar el análisis y el alcance que no se cumplen a través de nuestras ofertas estándar. Esta flexibilidad le ayudará a obtener la información exacta que necesita para la planificación y la toma de decisiones de su negocio.
Mercado de neuropatía periférica inducida por quimioterapia : ideas estratégicas
CAGR (2021 - 2028)5,4%- Tamaño del mercado 2021
US$ 813,48 millones - Tamaño del Mercado 2028
US$ 1.174,26 Millones
Dinámica del mercado
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
Jugadores claves . Jugadores principales
- FARMACÉUTICAS REGENACY , INC.
- CORPORACION FARMACIA ASAHI KASEI KASEI PHARMA CORPORATION
- NOVAREMED
- MAKSCIENTIFIC , LLC
- WEX PHARMACEUTICALS INC PHARMACEUTICALS INC
- FARMACÉUTICAS SOVA, INC. PHARMACEUTICALS, INC
- KINETA, INC., INC.
- APTINYX INC.
- InfobelFilipinasOtros Comercios & ServiciosApexian Pharmaceuticals, Inc.
Panorama regional
- América del norte
- Europa
- Asia-Pacífico
- América del Sur y Central
- Medio Oriente y África
Segmentación de mercado
- esteroides
- Antidepresivos
- Anticonvulsivo
- Narcóticos
- Farmacia minorista
- Farmacia hospitalaria
- Farmacia en línea
- El PDF de muestra muestra la estructura del contenido y la naturaleza de la información con análisis cualitativo y cuantitativo.
El informe ofrece información y un análisis en profundidad del mercado de neuropatía periférica inducida por quimioterapia (CIPN), enfatizando las tendencias del mercado, los avances tecnológicos y la dinámica del mercado. También proporciona un análisis del panorama competitivo de los principales actores del mercado en todo el mundo. Además, el informe incluye el impacto de la pandemia de COVID-19 en el mercado de la neuropatía periférica inducida por quimioterapia en todas las regiones. La pandemia ha creado tanto una crisis de salud pública como una crisis económica en todo el mundo. El mercado mundial de neuropatía periférica inducida por quimioterapia antes de la pandemia estaba en constante crecimiento debido a la regularidad de las pruebas de detección, las consultas y los tratamientos del cáncer. La primera ola de COVID-19 trastocó las consultas, seguimientos y despistajes de casos oncológicos. Además, las interrupciones en los ensayos clínicos y el suministro de medicamentos a los pacientes durante la etapa inicial de la pandemia de COVID-19 afectaron las áreas más cruciales del mercado de la neuropatía periférica inducida por quimioterapia. Un cambio de enfoque hacia el tratamiento rápido de COVID-19 llevó a negligencia hacia otras afecciones médicas. Además, la disminución en la detección de casos de cáncer y las sesiones de quimioterapia para el tratamiento obstaculizaron la demanda de diagnósticos y tratamientos de neuropatía periférica inducida por quimioterapia.
Perspectivas del mercado
La creciente prevalencia del cáncer impulsa el crecimiento del mercado de neuropatía periférica inducida por quimioterapia
El cáncer es una de las principales causas de muerte en todo el mundo. Según la Organización Mundial de la Salud (OMS), el cáncer fue la primera causa de muerte en personas menores de 70 años en 183 países y la cuarta causa de muerte entre la población de todas las edades en 123 países de todo el mundo en 2019. Además, según los datos publicados por la OMS en marzo de 2021, diferentes tipos de cáncer causaron ~10 millones de muertes en 2020.
Las formas de cáncer más prevalentes en el mundo, 2020
- El PDF de muestra muestra la estructura del contenido y la naturaleza de la información con análisis cualitativo y cuantitativo.
La creciente prevalencia del cáncer ha creado una carga para los sistemas de salud en todo el mundo, además de aumentar la demanda de quimioterapia. La neuropatía periférica inducida por la quimioterapia es un efecto adverso común de los fármacos anticancerígenos neurotóxicos, como los derivados del platino (cisplatino y oxaliplatino), los venenos para el huso [taxanos (paclitaxel y docetaxel), alcaloides de la vinca, vincristina, epotilonas y eribulina], bortezomib, y talidomida. La alta prevalencia de neuropatía periférica inducida por la quimioterapia genera preocupación entre los pacientes y sobrevivientes de cáncer y sus proveedores de atención médica, especialmente porque no existe una única forma efectiva de prevenir esta afección.
En un estudio realizado por "The Journal of the International Association for the Study of Pain", la prevalencia de neuropatía periférica inducida por la quimioterapia fue del 68,1% (57,7–78,4 cuando se midió en el primer mes después de la quimioterapia, 60,0% (36,4–81,6) en el tercer mes, y 30,0% (6,4–53,5) en el sexto mes o después. Por lo tanto, la creciente incidencia de neuropatía periférica inducida por quimioterapia con la creciente prevalencia de cáncer impulsa el crecimiento del mercado de neuropatía periférica inducida por quimioterapia.
Perspectivas basadas en clases de medicamentos
Según la clase de fármaco, el mercado de la neuropatía periférica inducida por quimioterapia se segmenta en esteroides, antidepresivos, anticonvulsivos y narcóticos. En 2021, el segmento de esteroides tuvo la mayor participación del mercado. Se espera que el segmento anticonvulsiones registre la tasa compuesta anual más rápida del 6,2% durante el período previsto.
Información basada en el canal de distribución
Según el canal de distribución, el mercado de neuropatía periférica inducida por quimioterapia se segmenta en farmacia hospitalaria, farmacia minorista y farmacia en línea. En 2021, el segmento de farmacia hospitalaria ocupó la mayor cuota de mercado. Además, se espera que el segmento de farmacias minoristas registre la CAGR más alta del 5,9% durante 2021-2028.
Los actores del mercado de la neuropatía periférica inducida por quimioterapia (CIPN) se centran en adoptar estrategias orgánicas, como el lanzamiento y la expansión de productos, para ampliar su huella y cartera de productos en todo el mundo, así como para satisfacer las crecientes demandas.
Alcance del informe de mercado de Neuropatía periférica inducida por quimioterapia
Por geografía
Según la geografía, el mercado de neuropatía periférica inducida por quimioterapia está segmentado en América del Norte (EE. UU., Canadá y México), Europa (Reino Unido, Alemania, Francia, Italia, España y resto de Europa), Asia Pacífico (China, Japón, India). , Australia, Corea del Sur y el resto de Asia Pacífico), Medio Oriente y África (EAU, Arabia Saudita, Sudáfrica y el resto de Medio Oriente y África) y América del Sur y Central (Brasil, Argentina y el resto del Sur). & Centroamérica).
Perfiles de la empresa
- Regenacy Pharmaceuticals, Inc.
- Corporación farmacéutica Asahi Kasei
- Novaremed
- Makscientific, Llc
- Wex Pharmaceuticals Inc.
- Productos farmacéuticos Sova, Inc.
- Kineta, Inc.
- Aptinyx Inc.
- Apexian Pharmaceuticals, Inc.
- Winsantor, Inc.
Alcance del informe de mercado de Neuropatía periférica inducida por quimioterapia
Atributo del informe | Detalles |
---|---|
Tamaño del mercado en 2021 | US$ 813,48 millones |
Tamaño del mercado para 2028 | US$ 1.174,26 millones |
CAGR global (2021 - 2028) | 5,4% |
Información histórica | 2019-2020 |
Período de pronóstico | 2022-2028 |
Segmentos cubiertos | Por clase de medicamento
|
Regiones y países cubiertos | América del norte
|
Líderes del mercado y perfiles clave de empresas |
|
- El PDF de muestra muestra la estructura del contenido y la naturaleza de la información con análisis cualitativo y cuantitativo.
Chemotherapy Induced Peripheral Neuropathy Market Report Scope
Report Attribute | Details |
---|---|
Market size in | US$ 813.48 Million |
Market Size by | US$ 1,174.26 Million |
Global CAGR | 5.4% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By Clase de fármaco
|
Regions and Countries Covered |
América del Norte
|
Market leaders and key company profiles |
|
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The chemotherapy induced peripheral neuropathy market majorly consists of the players such as Regenacy Pharmaceuticals, Inc, Asahi Kasei Pharma Corporation., Novaremed, Makscientific, Llc, Wex Pharmaceuticals Inc., Sova Pharmaceuticals, Inc., Kineta, Inc., Aptinyx Inc., Apexian Pharmaceuticals, Inc., and Winsantor, Inc. amongst others.
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents. Clinically, CIPN is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing CIPN; moreover, the possibilities of treating this syndrome are very limited.
The chemotherapy induced peripheral neuropathy market, by drug class, is bifurcated into steroids, antidepressants, anti-seizure medicines, and narcotics. In 2021, the steroids segment held the largest share of the market. The anti-seizure medicines segment of the chemotherapy induced peripheral neuropathy market is expected to witness growth in its demand at the fastest CAGR during the forecast period.
The factors that are driving and restraining factors that will affect the chemotherapy induced peripheral neuropathy market in the coming years. Major factors driving the market growth include the increasing prevalence of cancer and increasing preference for chemotherapy. Additionally, the growing clinical trials for chemotherapeutic drugs is likely to emerge as a significant future trend in the market during the forecast period. However, lack of consolidated guidelines for chemotherapy hamper the chemotherapy induced peripheral neuropathy market growth.
The List of Companies - Chemotherapy Induced Peripheral Neuropathy Market
- REGENACY PHARMACEUTICALS, INC
- ASAHI KASEI PHARMA CORPORATION
- NOVAREMED
- MAKSCIENTIFIC, LLC
- WEX PHARMACEUTICALS INC
- SOVA PHARMACEUTICALS, INC
- KINETA, INC.
- APTINYX INC.
- APEXIAN PHARMACEUTICALS, INC.
- WINSANTOR, INC
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.